X
All Data
Lead Product(s): Denileukin Diftitox,Anti-PD-1 agent
Therapeutic Area: Oncology Product Name: E7777
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Combination of E7777 with an anti-PD-1 agent provided clear benefit both in terms of tumor growth control, and a highly significant improvement in overall survival.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LNP3794,BI 1701963
Therapeutic Area: Oncology Product Name: BI 3011441
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 27, 2021
Details:
Lupin’s proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s KRAS inhibitor pipeline to address KRAS-driven cancers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): XL102
Therapeutic Area: Oncology Product Name: XL102
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: $29.5 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement December 07, 2020
Details:
Exelixis has exercised exclusive option for Aurigene’s novel CDK7 inhibitor under the companies’ July 2019 agreement. Exelixis has now assumed responsibility for the future clinical development, commercialization, and global manufacturing of the compound now known as XL102.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
